These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 22954684)

  • 1. A second target of benzamide riboside: dihydrofolate reductase.
    Roussel B; Johnson-Farley N; Kerrigan JE; Scotto KW; Banerjee D; Felczak K; Pankiewicz KW; Gounder M; Lin H; Abali EE; Bertino JR
    Cancer Biol Ther; 2012 Nov; 13(13):1290-8. PubMed ID: 22954684
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced degradation of dihydrofolate reductase through inhibition of NAD kinase by nicotinamide analogs.
    Hsieh YC; Tedeschi P; Adebisi Lawal R; Banerjee D; Scotto K; Kerrigan JE; Lee KC; Johnson-Farley N; Bertino JR; Abali EE
    Mol Pharmacol; 2013 Feb; 83(2):339-53. PubMed ID: 23197646
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modulation of dihydrofolate reductase gene expression in methotrexate-resistant human leukemia CCRF-CEM/E cells by antisense oligonucleotides.
    Morganti M; Coronnello M; Caciagli B; Biondi C; Quattrone A; Capaccioli S; Mazzei T; Mini E
    Anticancer Drugs; 2000 Apr; 11(4):285-94. PubMed ID: 10898545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amplification of the dihydrofolate reductase gene is a mechanism of acquired resistance to methotrexate in patients with acute lymphoblastic leukemia and is correlated with p53 gene mutations.
    Göker E; Waltham M; Kheradpour A; Trippett T; Mazumdar M; Elisseyeff Y; Schnieders B; Steinherz P; Tan C; Berman E
    Blood; 1995 Jul; 86(2):677-84. PubMed ID: 7605998
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Maintenance of differential methotrexate toxicity between cells expressing drug-resistant and wild-type dihydrofolate reductase activities in the presence of nucleosides through nucleoside transport inhibition.
    Warlick CA; Sweeney CL; McIvor RS
    Biochem Pharmacol; 2000 Jan; 59(2):141-51. PubMed ID: 10810448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular mechanisms of resistance to antifolates, a review.
    Banerjee D; Ercikan-Abali E; Waltham M; Schnieders B; Hochhauser D; Li WW; Fan J; Gorlick R; Goker E; Bertino JR
    Acta Biochim Pol; 1995; 42(4):457-64. PubMed ID: 8852336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies on the mechanism of action of benzamide riboside: a novel inhibitor of IMP dehydrogenase.
    Gharehbaghi K; Grünberger W; Jayaram HN
    Curr Med Chem; 2002 Apr; 9(7):743-8. PubMed ID: 11966437
    [TBL] [Abstract][Full Text] [Related]  

  • 8. DHFR and MSH3 co-amplification in childhood acute lymphoblastic leukaemia, in vitro and in vivo.
    Matheson EC; Hogarth LA; Case MC; Irving JA; Hall AG
    Carcinogenesis; 2007 Jun; 28(6):1341-6. PubMed ID: 17148505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN; O'Connor A; Grant MR; Yang H; Grieco PA; Cooney DA
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dihydrofolate Reductase and Thymidylate Synthase Transgenes Resistant to Methotrexate Interact to Permit Novel Transgene Regulation.
    Rushworth D; Mathews A; Alpert A; Cooper LJ
    J Biol Chem; 2015 Sep; 290(38):22970-6. PubMed ID: 26242737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytotoxicity and characterization of an active metabolite of benzamide riboside, a novel inhibitor of IMP dehydrogenase.
    Gharehbaghi K; Paull KD; Kelley JA; Barchi JJ; Marquez VE; Cooney DA; Monks A; Scudiero D; Krohn K; Jayaram HN
    Int J Cancer; 1994 Mar; 56(6):892-9. PubMed ID: 7907081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer research: from folate antagonism to molecular targets.
    Bertino JR
    Best Pract Res Clin Haematol; 2009 Dec; 22(4):577-82. PubMed ID: 19959110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simultaneous Inhibition of Protein Kinase CK2 and Dihydrofolate Reductase Results in Synergistic Effect on Acute Lymphoblastic Leukemia Cells.
    Wińska P; Widło Ł; Skierka K; Krzyśko A; Koronkiewicz M; Cieśla JM; Cieśla J; Bretner M
    Anticancer Res; 2019 Jul; 39(7):3531-3542. PubMed ID: 31262877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of CCRF-CEM human lymphoid cells from antifolates by retroviral gene transfer of variants of murine dihydrofolate reductase.
    Mareya SM; Sorrentino BP; Blakley RL
    Cancer Gene Ther; 1998; 5(4):225-35. PubMed ID: 9694074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced folate carrier and dihydrofolate reductase expression in acute lymphocytic leukemia may predict outcome: a Children's Cancer Group Study.
    Levy AS; Sather HN; Steinherz PG; Sowers R; La M; Moscow JA; Gaynon PS; Uckun FM; Bertino JR; Gorlick R;
    J Pediatr Hematol Oncol; 2003 Sep; 25(9):688-95. PubMed ID: 12972803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of the novel IMP dehydrogenase inhibitor benzamide riboside.
    Jäger W; Salamon A; Szekeres T
    Curr Med Chem; 2002 Apr; 9(7):781-6. PubMed ID: 11966442
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase.
    Banerjee D; Mayer-Kuckuk P; Capiaux G; Budak-Alpdogan T; Gorlick R; Bertino JR
    Biochim Biophys Acta; 2002 Jul; 1587(2-3):164-73. PubMed ID: 12084458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of biochemical parameters of benzamide riboside, a new inhibitor of IMP dehydrogenase, with tiazofurin and selenazofurin.
    Gharehbaghi K; Sreenath A; Hao Z; Paull KD; Szekeres T; Cooney DA; Krohn K; Jayaram HN
    Biochem Pharmacol; 1994 Oct; 48(7):1413-9. PubMed ID: 7945441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sensitization of human erythroleukemia K562 cells resistant to methotrexate by inhibiting IMPDH.
    Peñuelas S; Noé V; Morales R; Ciudad CJ
    Med Sci Monit; 2005 Jan; 11(1):BR6-12. PubMed ID: 15614187
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Benzamide riboside, a recent inhibitor of inosine 5'-monophosphate dehydrogenase induces transferrin receptors in cancer cells.
    Szekeres T; Sedlak J; Novotny L
    Curr Med Chem; 2002 Apr; 9(7):759-64. PubMed ID: 11966439
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.